Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 6Recurrence 2Lymphoma 2Wilms Tumor 1Plasmacytoma 1Paraproteinemias 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cytarabine 75Etoposide 31Daunorubicin 27Filgrastim 24Mitoxantrone 23Idarubicin 23Busulfan 22Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 20fludarabine phosphate 19Gemtuzumab 14tipifarnib 11Antilymphocyte Serum 11Radiotherapy 10Methotrexate 10Cyclosporine 10Clofarabine 10sargramostim 9Gene Expression Profiling 9Flow Cytometry 9Azacitidine 9alvocidib 6aldesleukin 6Whole-Body Irradiation 6Vorinostat 6Topotecan 6Tacrolimus 6Bortezomib 6valspodar 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Erythroblastic, Acute × Proteasome Inhibitors × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡